SGLT2i have been shown to be effective in lowering blood sugar levels in people with type 2 diabetes. They are also associated with a lower risk of cardiovascular events, such as heart attacks and strokes. SGLT2i are generally well-tolerated, but can cause side effects such as urinary tract...
5月6日,阿斯利康的SGLT2抑制剂达格列净(dapagliflozin,英文商品名Farxiga)成功扩展适应症,获FDA批准用于治疗射血分数降低的心力衰竭(HF)成人患者,以降低心血管死亡和因心力衰竭住院的风险。据悉,这也是首个被批准用于治疗伴有射血分数降低的心力衰竭成人患者(他们可能患有或不患有糖尿病)的SGLT2抑制剂。 由于心脏无法...
今日,阿斯利康(AstraZeneca)宣布,其SGLT2抑制剂达格列净(dapagliflozin,英文商品名Farxiga),在射血分数轻度降低或射血分数保留型心衰患者中进行的3期临床试验中达到主要终点,为心血管死亡或心衰恶化风险提供具有统计显著和临床意义的改善。新闻稿指出,结合此前在射血分数降低型患者中进行的临床试验,这些结果显示无论射血...